Transaction · 0001822629-26-000014

Lalwani Nikhil

Lalwani Nikhil, PRES, CEO, reported an open-market or private sale at ANI PHARMACEUTICALS INC involving 5400.000000 shares for an estimated $401220.00. Reported holdings after the transaction were 344489.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, CEO
ANIPANI PHARMACEUTICALS INC
Filing timeAug 26
Trade dateAug 25, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

ANIP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ANIP since 2026-08-26Filed 9 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001822629-26-000014
Common Stock
Transaction date
Aug 25, 2026
Filed Aug 26, 2026, 10:15 PM · 1d delay
Shares
5.40k sh
$7.43k per share
Estimated value
-$40.1M
Computed from shares × price
Holdings after
344k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

PRESIDENT & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.

  2. F2

    The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price.

Original filing · 0001822629-26-000014
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ANIP